Christopher Larson

2.3k total citations · 1 hit paper
40 papers, 1.8k citations indexed

About

Christopher Larson is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Christopher Larson has authored 40 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 14 papers in Molecular Biology and 12 papers in Genetics. Recurrent topics in Christopher Larson's work include CAR-T cell therapy research (13 papers), Drug Transport and Resistance Mechanisms (13 papers) and Virus-based gene therapy research (12 papers). Christopher Larson is often cited by papers focused on CAR-T cell therapy research (13 papers), Drug Transport and Resistance Mechanisms (13 papers) and Virus-based gene therapy research (12 papers). Christopher Larson collaborates with scholars based in United States, South Africa and Finland. Christopher Larson's co-authors include Stephen B. Howell, Roohangiz Safaei, Brian Blair, Bryan Oronsky, Tony R. Reid, Arnold L. Oronsky, Michael J. Sailor, Santosh Kesari, Michelle Lybeck and Terese Hammond and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Frontiers in Immunology.

In The Last Decade

Christopher Larson

40 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Review of Persistent Post-COVID Syndrome (PPCS)

2021 269 citations Bryan Oronsky, Christopher Larson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher Larson United States	18	915	549	453	197	183	40	1.8k
Wei‐Qun Ding United States	20	345 0.4×	1.3k 2.3×	244 0.5×	42 0.2×	38 0.2×	62	1.9k
Tetsuya Ogino Japan	25	373 0.4×	654 1.2×	117 0.3×	74 0.4×	52 0.3×	67	2.0k
Aru Narendran Canada	25	516 0.6×	908 1.7×	55 0.1×	178 0.9×	138 0.8×	115	1.7k
Zhanjun Hou United States	27	261 0.3×	1.1k 2.1×	146 0.3×	33 0.2×	87 0.5×	80	1.9k
Chien-Shing Chen United States	24	389 0.4×	1.1k 2.0×	97 0.2×	45 0.2×	67 0.4×	60	2.0k
Jennifer L. Hsu United States	23	1.3k 1.4×	1.5k 2.7×	108 0.2×	37 0.2×	132 0.7×	55	3.2k
Bethany N. Hannafon United States	19	252 0.3×	1.8k 3.4×	143 0.3×	36 0.2×	63 0.3×	40	2.3k
Lars H. Breimer United Kingdom	19	267 0.3×	1.3k 2.4×	82 0.2×	116 0.6×	175 1.0×	68	2.1k
Jinchang Wu China	20	274 0.3×	876 1.6×	124 0.3×	32 0.2×	33 0.2×	56	1.5k
Sarah M. Planchon United States	22	338 0.4×	1.2k 2.2×	84 0.2×	111 0.6×	95 0.5×	39	2.3k

Countries citing papers authored by Christopher Larson

Since Specialization

Citations

This map shows the geographic impact of Christopher Larson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Larson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Larson more than expected).

Fields of papers citing papers by Christopher Larson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Larson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Larson. The network helps show where Christopher Larson may publish in the future.

Co-authorship network of co-authors of Christopher Larson

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Larson. A scholar is included among the top collaborators of Christopher Larson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Larson. Christopher Larson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reid, Tony, Christopher Larson, Bryan Oronsky, et al.. (2024). CAR expression in invasive breast carcinoma and its effect on adenovirus transduction efficiency. Breast Cancer Research. 26(1). 131–131. 1 indexed citations

Larson, Christopher, Omonigho Aisagbonhi, Sarah L. Blair, et al.. (2023). A Local and Abscopal Effect Observed with Liposomal Encapsulation of Intratumorally Injected Oncolytic Adenoviral Therapy. Cancers. 15(12). 3157–3157. 6 indexed citations

Conley, Anthony P., Christina L. Roland, Alberto Bessudo, et al.. (2023). BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors. Cancer Gene Therapy. 31(4). 517–526. 4 indexed citations

Conley, Anthony P., Christina L. Roland, Brian Gastman, et al.. (2023). Initial results from a first in human dose escalation trial of a novel immune stimulating oncolytic adenovirus, AdAPT-001^{TGF-ß Trap}.. Journal of Clinical Oncology. 41(16_suppl). 2550–2550. 2 indexed citations

Reid, Tony R., Scott Caroen, Bryan Oronsky, et al.. (2022). ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal Cancer. Clinical Colorectal Cancer. 22(1). 92–99. 14 indexed citations

Oronsky, Bryan, et al.. (2022). Nucleocapsid as a next-generation COVID-19 vaccine candidate. International Journal of Infectious Diseases. 122. 529–530. 21 indexed citations

Larson, Christopher, Bryan Oronsky, & Tony Reid. (2022). AdAPT-001, an oncolytic adenovirus armed with a TGF-β trap, overcomes in vivo resistance to PD-L1-immunotherapy.. PubMed. 12(7). 3141–3147. 9 indexed citations

Oronsky, Bryan, Tony R. Reid, Christopher Larson, et al.. (2019). REPLATINUM Phase III Randomized Study: RRx-001 + Platinum Doublet Versus Platinum Doublet in Third-Line Small Cell Lung Cancer. Future Oncology. 15(30). 3427–3433. 47 indexed citations

Oronsky, Bryan, Tony R. Reid, Christopher Larson, et al.. (2017). RRx-001 protects against cisplatin-induced toxicities. Journal of Cancer Research and Clinical Oncology. 143(9). 1671–1677. 19 indexed citations

10.

Hedjran, Farah, et al.. (2014). A novel immunocompetent murine model for replicating oncolytic adenoviral therapy. Cancer Gene Therapy. 22(1). 17–22. 28 indexed citations

11.

Tsai, Cheng‐Yu, Christopher Larson, Roohangiz Safaei, & Stephen B. Howell. (2014). Molecular modulation of the copper and cisplatin transport function of CTR1 and its interaction with IRS-4. Biochemical Pharmacology. 90(4). 379–387. 17 indexed citations

12.

Abada, Paolo, et al.. (2012). Sec61β Controls Sensitivity to Platinum-Containing Chemotherapeutic Agents through Modulation of the Copper-Transporting ATPase ATP7A. Molecular Pharmacology. 82(3). 510–520. 14 indexed citations

13.

Tsigelny, Igor F., Yuriy Sharikov, Jerry P. Greenberg, et al.. (2012). An All-Atom Model of the Structure of Human Copper Transporter 1. Cell Biochemistry and Biophysics. 63(3). 223–234. 40 indexed citations

14.

Blair, Brian, et al.. (2010). Regulation of Copper Transporter 2 Expression by Copper and Cisplatin in Human Ovarian Carcinoma Cells. Molecular Pharmacology. 77(6). 912–921. 41 indexed citations

15.

Larson, Christopher, et al.. (2010). The role of the N-terminus of mammalian copper transporter 1 in the cellular accumulation of cisplatin. Biochemical Pharmacology. 80(4). 448–454. 51 indexed citations

16.

Larson, Christopher, et al.. (2010). The Role of the Methionines and Histidines in the Transmembrane Domain of Mammalian Copper Transporter 1 in the Cellular Accumulation of Cisplatin. Molecular Pharmacology. 78(3). 333–339. 34 indexed citations

17.

Howell, Stephen B., Roohangiz Safaei, Christopher Larson, & Michael J. Sailor. (2010). Copper Transporters and the Cellular Pharmacology of the Platinum-Containing Cancer Drugs. Molecular Pharmacology. 77(6). 887–894. 276 indexed citations

18.

Blair, Brian, Christopher Larson, Paolo Abada, et al.. (2010). Copper Transporter 2 Regulates Endocytosis and Controls Tumor Growth and Sensitivity to Cisplatin In Vivo. Molecular Pharmacology. 79(1). 157–166. 58 indexed citations

19.

Larson, Christopher, Brian Blair, Roohangiz Safaei, & Stephen B. Howell. (2008). The Role of the Mammalian Copper Transporter 1 in the Cellular Accumulation of Platinum-Based Drugs. Molecular Pharmacology. 75(2). 324–330. 146 indexed citations

20.

Blair, Norman P., Ting Liu, Keith Warren, et al.. (2004). OCULAR OXYGEN CONSUMPTION: ESTIMATES USING VITREOPERFUSION IN THE CAT. Retina. 24(1). 120–131. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact